SCHEMBL27959639

SCHEMBL27959639

[CH2]C(O)Cc1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 2/20 0.50
TAAR1 Q96RJ0 4/20 0.47
IDO1 P14902 2/20 0.46
AGXT P21549 2/20 0.46
PPARG P37231 4/20 0.43
PPARA Q07869 3/20 0.43
MIF P14174 1/20 0.42
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MPO P05164 1/20 0.41
MDM2 Q00987 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6224951 0.83 SLC1A1 (0.53) SLC1A1TAAR1IDO1AGXTPPARG
SCHEMBL4965957 0.82 SLC1A1 (0.51) SLC1A1TAAR1IDO1AGXTPPARG
SCHEMBL1992923 0.82 SLC1A1 (0.51) SLC1A1TAAR1IDO1AGXTPPARG
SCHEMBL2427588 0.80 SLC1A1 (0.50) SLC1A1TAAR1IDO1AGXTPPARG
SCHEMBL4426896 0.80 SLC1A1 (0.50) SLC1A1TAAR1IDO1AGXTPPARG
SCHEMBL4422549 0.80 SLC1A1 (0.50) SLC1A1TAAR1IDO1AGXTPPARG
SCHEMBL27959407 0.79 IDO1 (0.38) IDO1
SCHEMBL15066444 0.78 SLC1A1 (0.49) SLC1A1TAAR1IDO1AGXTPPARG
SCHEMBL31435827 0.78 SLC1A1 (0.49) SLC1A1TAAR1IDO1AGXT
SCHEMBL10586409 0.78 SLC1A1 (0.49) SLC1A1TAAR1IDO1AGXTPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103848859-A Surface modifier for transparent oxide electrode, surface-modified transparent oxide electrode, and method for producing same SHINETSU CHEMICAL CO 2014-06-11 CN disclosed
CN-101309904-A 1- (1H-indol-1-yl) -3- (methylamino) -1-phenylpropan-2-ol derivatives and related compounds as monoamine reuptake modulators for the treatment of vasomotor symptoms (VMS) WYETH CORP (US) 2008-11-19 CN disclosed